CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1 Dose Escalation Study of CPX-351 for Patients With Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia After Failure to Hypomethylating Agents

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03896269
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:55.492889+00:00
Published At: 2026-04-14T00:00:00+00:00
Record Updated At: 2026-04-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Blasts 10-19 Percent of Bone Marrow Nucleated Cells", "Blasts More Than 5 Percent of Bone Marrow Nucleated Cells", "High Risk Chronic Myelomonocytic Leukemia", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent High Risk Myelodysplastic Syndrome", "Refractory Chronic Myelomonocytic Leukemia", "Refractory High Risk Myelodysplastic Syndrome"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-14"
protocolSection.identificationModule.nctId: "NCT03896269"
protocolSection.identificationModule.officialTitle: "Phase 1 Dose Escalation Study of CPX-351 for Patients With Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia After Failure to Hypomethylating Agents"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.